New funding accelerates Solace’s expansion establishing healthcare advocacy as essential infrastructure for closing the gaps between diagnosis and treatment.

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Solace Health today announced a $130 million Series C funding round led by IVP, accelerating the company’s mission to make advocacy a standard part of care for every patient in the United States. The Series C values Solace at over $1 billion and reflects growing consensus that healthcare advocacy is no longer optional as costs rise and systems fracture. The round also included participation from existing investors Menlo Ventures, SignalFire, Torch Capital, Inspired Capital and RiverPark Ventures.

“This partnership allows us to embed advocacy earlier in care, at national scale, and establish it as a permanent part of how healthcare works in the United States,” said Jeremy Gurewitz, CEO and co-founder of Solace.Share

Despite unprecedented healthcare spending, millions of Americans still struggle to access timely, coordinated care, and nearly 40% delay or avoid care altogether due to cost and complexity. These gaps drive missed diagnoses, avoidable hospitalizations, caregiver burnout, and billions in unnecessary spend. Solace exists to close that gap.

Solace is a patient-centric healthcare advocacy layer that sits alongside clinical care. The company connects patients and families with trained healthcare advocates who coordinate care across providers, manage logistics, and surface options that help patients move forward with confidence. By intervening between diagnosis and treatment where patients are most vulnerable, Solace shortens time-to-care, reduces friction, and improves outcomes at scale.

Solace’s model is also designed around the professionals delivering advocacy. By establishing a dedicated advocacy role with clear scope and strong technological support, Solace enables experienced nurses and care specialists to focus on judgment and patient guidance, building durable relationships over time and reinforcing the quality and consistency that better outcomes require.

With this funding, Solace will significantly expand its national network of more than 2,000 experienced advocates serving Medicare and Medicare Advantage members, while accelerating investment in its platform and clinical research. The company will also deepen partnerships with payers and providers to embed advocacy earlier in the care journey where outcomes are most at risk.

Solace was founded by CEO Jeremy Gurewitz and Chief Product Officer Sara Sargent. The concept was born from Jeremy’s experience advocating for his mother, an accomplished radiologist who struggled to navigate her own pancreatic cancer diagnosis despite her medical expertise. This experience exposed a stark truth: if a physician needs an advocate, the system is fundamentally broken for everyone else.

Today, Solace serves more than 20,000 patients monthly through its HIPAA-compliant platform, connecting them with expert advocates via text, phone, and video. With 10x year-over-year growth and IVP’s backing, the company is poised to scale its model nationwide and shorten time-to-diagnosis, reduce avoidable hospitalizations, and materially improve patient outcomes.

“The healthcare system has normalized leaving patients to figure things out themselves in their vulnerable moments,” said Jeremy Gurewitz, CEO and co-founder of Solace. “That failure is costly, dangerous, and preventable. IVP understands how to scale companies where execution and consequences are inseparable. This partnership allows us to embed advocacy earlier in care, at national scale, and establish it as a permanent part of how healthcare works in the United States.”

“Healthcare advocacy is moving from a discretionary service to essential infrastructure,” said Eric Liaw, General Partner at IVP. “Solace has demonstrated that when patients are supported through complexity, outcomes improve and costs come down. We believe Solace is building a foundational layer of the healthcare system, and the scale of this opportunity is significant.”

Solace’s Series C marks a step toward a future where patients are no longer left to navigate care alone, and where better outcomes begin with support that’s embedded into care itself.

About Solace Health

Solace Health (Solace) is a digital platform that connects patients with expert healthcare advocates who navigate the healthcare system on their behalf, improving outcomes and reducing costs. Founded in 2022 by Jeremy Gurewitz and Sara Sargent after their own experiences with a fragmented healthcare system, Solace empowers patients to take control of their care journeys. Solace advocates coordinate appointments, manage treatment plans, and ensure continuity of care, helping patients and families overcome the obstacles that stand between them and better outcomes. Learn more at www.solacehealth.com.

About IVP

IVP helps ambitious founders build era-defining companies, converting momentum into market dominance. One of the original venture firms on Sand Hill Road, IVP partners with companies at the moment of product-market-fit—from Slack, Crowdstrike and Coinbase to Perplexity, Abridge, Glean and Chainguard. We’ve guided market leaders through cycles and storms, unlocking pivotal growth by activating the right expertise at the moments founders need it. With 130+ IPOs out of 400 investments, IVP helps undaunted founders defy limits, command industries and cement their place at the top.

Contacts

Media Contact
The Colab
solace@colabcomms.co

(c)2026 Business Wire, Inc., All rights reserved.